Solid Biosciences Inc.

Solid Biosciences Inc. is a life sciences company that develops gene therapies for rare neuromuscular and cardiac diseases. Its research and development efforts focus on gene transfer candidates designed to deliver functional transgenes to treat conditions caused by mutated genes. The company's pipeline includes investigational therapies such as SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for dilated cardiomyopathy. Because its pipeline remains in development, the company does not currently sell commercial products, and its target end-users are patients suffering from these conditions.

The company's principal executive offices and laboratory spaces are located in Charlestown, Massachusetts. Solid Biosciences operates in the United States and relies on external contract manufacturers to produce its drug candidates. Additionally, the company maintains collaborative and licensing relationships with domestic academic centers and medical organizations, including the Mayo Clinic, the University of Florida, and the University of Washington.

Summary of the business section of Solid Biosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 121 full-time employees, including 89 in research and development and 32 in general and administrative positions, and of which 26 of our employees hold Ph.D.”